- Rapid Dose Therapeutics (CSE:DOSE) has revealed a collaboration with the National Football League for a funded clinical trial program
- The program is called Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in Contact Sports and will take place at the University of Regina
- The company will participate in a randomized two-arm clinical study, which aims to determine the relative oral bioavailability and pharmacokinetic parameters of the cannabidiol
- Shares of Rapid Dose Therapeutics are unchanged at C$0.22
Rapid Dose Therapeutics (CSE:DOSE) has revealed a collaboration with the National Football League (NFL) for a funded clinical trial program.
The company stated in a news release that the program, called Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in Contact Sport, will take place at the University of Regina in Saskatchewan.
As part of the study, Rapid Dose Therapeutics stated it will participate in a randomized two-arm clinical study that aims to determine the relative oral bioavailability and pharmacokinetic parameters of the cannabidiol (CBD).
“This study has the potential to change not only the lives of current and former NFL players, but also the lives of anyone who may suffer from a concussion,” Patrick Neary, exercise physiologist and professor in the Faculty of Kinesiology and Health Studies at the University of Regina, said in a statement.
The primary objective of the study will be to determine the relative oral bioavailability and other pharmacokinetic parameters of the non-psychoactive cannabidiol and its metabolites, when administered to a healthy young adult population as RDT’s sublingual QuickStrip product when compared with a standard oral formulation.
Data from the study aims to prove the efficacy of the QuickStrip product and serve as the basis for including RDT’s QuickStrip in subsequent clinical studies as part of the overall clinical program funded by the NFL.
Rapid Dose Therapeutics is a biotechnology company focused on its flagship QuickStrip product, which is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines.
Shares of Rapid Dose Therapeutics (CSE:DOSE) are unchanged at C$0.22.
Join the discussion: Find out what everybody’s saying about this stock on the Rapid Dose Therapeutics Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.